‘More Is Not Better’ in Metastatic Castration-Resistant Prostate Cancer
This study compared combination therapy with enzalutamide, abiraterone, and prednisone vs enzalutamide alone in men with metastatic castration-resistant prostate cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news